Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.36 |
| ▸ | RHEB | Q15382 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 8/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12066027 | 0.89 | RHEB (0.35) | SCN10ARHEBPDE2A | |
| SCHEMBL12065647 | 0.81 | SCN10A (0.40) | SCN10APDE2AGRIN2B | |
| SCHEMBL12066025 | 0.78 | SCN10A (0.45) | SCN10APDE2A | |
| SCHEMBL12066030 | 0.77 | PDE2A (0.38) | SCN10APDE2A | |
| SCHEMBL12065286 | 0.77 | SCN10A (0.38) | SCN10APDE2A | |
| SCHEMBL14763552 | 0.76 | SCN10A (0.43) | SCN10APDE2A | |
| SCHEMBL12065657 | 0.76 | MLKL (0.51) | SCN10A | |
| SCHEMBL12065255 | 0.75 | SCN10A (0.40) | SCN10APDE2A | |
| SCHEMBL14762773 | 0.75 | SCN10A (0.43) | SCN10APDE2A | |
| SCHEMBL12065287 | 0.75 | SCN10A (0.36) | SCN10APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578573-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA Eiyo Ltd. (JP) | 2013-04-10 | — | — | EP | claimed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | claimed |
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| EP-2578573-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA Eiyo Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| WO-2011148956-A1 | FUSED IMIDAZOLE DERIVATIVE | トーアエイヨー株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | SCN10A 85/4885RHEB 3477/4885PDE2A 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.